Pyxis Oncology (PYXS) News Today $0.92 +0.00 (+0.48%) As of 12:36 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology ForumApril 2, 2025 | globenewswire.comPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025March 25, 2025 | globenewswire.comStifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)March 24, 2025 | markets.businessinsider.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy rMarch 23, 2025 | marketbeat.comHC Wainwright Forecasts Stronger Earnings for Pyxis OncologyPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Research analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report released on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earninMarch 22, 2025 | marketbeat.comWilliam Blair Comments on Pyxis Oncology Q1 EarningsPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at William Blair issued their Q1 2025 earnings per share estimates for Pyxis Oncology in a report released on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.32) for the quMarch 22, 2025 | marketbeat.comWilliam Blair Comments on Pyxis Oncology FY2027 EarningsPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Research analysts at William Blair issued their FY2027 EPS estimates for Pyxis Oncology in a report released on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will earn ($1.27) per share for the year. William BlairMarch 21, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday.March 20, 2025 | marketbeat.comRBC Capital Remains a Buy on Pyxis Oncology (PYXS)March 20, 2025 | markets.businessinsider.comPyxis Oncology's (PYXS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Wednesday.March 20, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Releases Earnings Results, Hits ExpectationsPyxis Oncology (NASDAQ:PYXS - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.32).March 19, 2025 | marketbeat.comPyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)March 19, 2025 | markets.businessinsider.comPyxis Oncology (PYXS) Gets a Hold from William BlairMarch 19, 2025 | markets.businessinsider.comPyxis Oncology Advances Cancer Therapeutics with MICVOMarch 18, 2025 | tipranks.comPyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 18, 2025 | globenewswire.comPyxis Oncology (PYXS) to Release Earnings on ThursdayPyxis Oncology (NASDAQ:PYXS) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comPyxis Oncology to Participate at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comPyxis Oncology granted Fast Track designation for PYX-201 monotherapyFebruary 26, 2025 | markets.businessinsider.comPyxis Oncology rises on FDA fast track tag for lead assetFebruary 26, 2025 | msn.comPyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck CancerFebruary 26, 2025 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy rFebruary 26, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% - Here's What HappenedPyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% - Should You Sell?February 25, 2025 | marketbeat.comPyxis Oncology initiates new PYX-201 trial, initiates cohort expansionsFebruary 4, 2025 | markets.businessinsider.comPyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy TrialFebruary 4, 2025 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from AnalystsPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The aFebruary 1, 2025 | marketbeat.comPyxis Oncology stock outlook adjusted with focus on ADC program and cost managementDecember 26, 2024 | uk.investing.comPyxis Oncology price target lowered to $8 from $10 at RBC CapitalDecember 21, 2024 | markets.businessinsider.comStrategic Focus on PYX-201 Drives Positive Buy Rating for Pyxis OncologyDecember 20, 2024 | markets.businessinsider.comPyxis Oncology’s Strategic Focus on PYX-201 and Collaboration with Merck Drives Buy RatingDecember 20, 2024 | markets.businessinsider.comRoyal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS)Royal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday.December 20, 2024 | marketbeat.comPyxis Oncology to prioritize PYX-201, suspends investment in PYX-106December 20, 2024 | markets.businessinsider.comPyxis Oncology to Focus on PYX-201, Suspends PYX-106 ProgramDecember 19, 2024 | marketwatch.comPyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201December 19, 2024 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have issued a bDecember 13, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Invests $1.41 Million in Pyxis Oncology, Inc. (NASDAQ:PYXS)Jacobs Levy Equity Management Inc. purchased a new stake in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 382,840 shares of the company's stock, valued at approximately $1,405,000. Jacobs Levy Equity MDecember 9, 2024 | marketbeat.comPyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts AheadDecember 7, 2024 | seekingalpha.comCFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More SharesDecember 1, 2024 | finance.yahoo.comPyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy Purchases 88,850 SharesNovember 28, 2024 | insidertrades.comPyxis Oncology's SWOT analysis: ADC innovator's stock poised for growthNovember 27, 2024 | uk.investing.comInstitutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the greenNovember 27, 2024 | finance.yahoo.comRBC ups Pyxis Oncology target, says buy shares on selloffNovember 23, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Pyxis Oncology (PYXS)November 23, 2024 | markets.businessinsider.comPyxis Oncology downgraded to Market Perform from Outperform at William BlairNovember 22, 2024 | markets.businessinsider.comPyxis Oncology reported ‘compelling’ cancer dataset, says H.C. WainwrightNovember 22, 2024 | markets.businessinsider.comWilliam Blair Downgrades Pyxis Oncology (PYXS)November 22, 2024 | msn.comPyxis stock craters 46% amid Phase 1 data, William Blair downgradeNovember 22, 2024 | msn.comPyxis Oncology's Cancer Drug Progress Stirs Analyst ConcernsNovember 21, 2024 | benzinga.comHC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday.November 21, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Downgraded to "Market Perform" Rating by William BlairWilliam Blair cut Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday.November 21, 2024 | marketbeat.comPyxis Oncology Reports Promising Phase 1 Trial ResultsNovember 21, 2024 | markets.businessinsider.com Remove Ads Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address PYXS Media Mentions By Week PYXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYXS News Sentiment▼1.890.80▲Average Medical News Sentiment PYXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYXS Articles This Week▼12▲PYXS Articles Average Week Remove Ads Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SLRN News CADL News SLDB News ACB News PVLA News OLMA News CMPX News IMMP News DRUG News FHTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYXS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
